FIELD: medicine, oncology, pharmacy.
SUBSTANCE: invention proposes a composition comprising serotonin salts with pharmaceutically acceptable acids and mellitine in the ratio 0.5-25 moles of serotonin salt per 1 mole of mellitine, 10 moles of serotonin salt per 1 mole of mellitine. Invention provides preparing the composition possessing broad range of antimetastatic effect.
EFFECT: valuable medicinal property of composition.
2 cl, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR INHIBITION OF METASTASIS IN LUNGS | 2016 |
|
RU2632703C1 |
| DRUG WITH ANTIPROLIFERATIVE AND ANTIMETASTATIC EFFECTS AGAINST LEWIS LUNG CARCINOMA WHEN INJECTED INTRAPERITONEALLY | 2022 |
|
RU2792144C1 |
| ANGIOGENESIS INHIBITOR, ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF MALIGNANT NEOPLASM | 2005 |
|
RU2287341C1 |
| ANTI-TUMOUR AGENT AGAINST LUNG TUMOUR | 2021 |
|
RU2765472C1 |
| ANTINEOPLASTIC AGENT | 2016 |
|
RU2623034C1 |
| METHOD OF TUMOR METASTASIS TREATMENT | 1990 |
|
RU2112514C1 |
| METHOD OF MODIFYING THE DEVELOPMENT OF ADENOCARCINOMA EXPERIMENTALLY | 2020 |
|
RU2743960C1 |
| MEANS FOR INHIBITING METASTASIS IN THE LUNGS | 2021 |
|
RU2762730C1 |
| USE OF GOLD POLYACRYLATE AS A HUMAN MELANOMA CELL GROWTH INHIBITOR | 2018 |
|
RU2708626C1 |
| COMPOSITION AND UTILIZATION OF ET743 FOR MALIGNANT TUMOR TREATMENT | 2000 |
|
RU2266734C2 |
